STOCK TITAN

IRIDEX Q3 2026 revenue falls 19% to $10.2M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

IRIDEX Corporation (IRIX) reported third-quarter 2026 revenue of $10.2 million, down 19% from $12.5 million a year earlier. Net loss was $1.4 million, compared with $1.6 million, while non-GAAP adjusted EBITDA loss was $0.6 million, versus $0.1 million. Gross margin was 42.4%, compared with 32.1%; the prior-year quarter included an approximately $0.8 million inventory write-off.

The company reduced 2026 revenue guidance to $46 million to $48 million from $51 million to $53 million; the outlook continues to exclude Middle East revenue. Adjusted operating expense guidance remains $19 million to $19.5 million, excluding depreciation and amortization and stock-based compensation. Cash and cash equivalents were $3.7 million as of October 3, 2026, down $1.0 million from July 4, 2026.

IRIDEX completed its headquarters relocation to San Jose, which it expects to deliver approximately $600,000 in annualized savings. Management cited weaker-than-expected demand in Europe and Asia, distributor probe inventory drawdowns and late-quarter order delays. It expects cash utilization to decrease significantly in the fourth quarter with stronger sales and consumption of safety stock inventory.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointGross margin was 42.4%, compared with 32.1% a year earlier.
  • Minor pointNet loss narrowed to $1.4 million from $1.6 million.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.2026 revenue guidance was reduced to $46 million to $48 million from $51 million to $53 million.
  • Moderate pointRevenue fell 19% to $10.2 million, primarily as international retina sales and probe orders declined.
  • Moderate pointAdjusted EBITDA loss was $0.6 million, compared with $0.1 million a year earlier.

Filing Explained

At October 3, 2026, IRIDEX reported a convertible note payable, $6 million of Series B convertible preferred stock, and total stockholders’ equity.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter revenue $10.2 million Third quarter 2026; down 19% from $12.5 million in the prior-year period
2026 revenue guidance $46 million to $48 million Reduced from $51 million to $53 million; excludes Middle East revenue
Gross margin 42.4% Third quarter 2026, compared with 32.1% in the prior-year period
Net loss $1.4 million Third quarter 2026, compared with $1.6 million in the prior-year period
Adjusted EBITDA loss $0.6 million Non-GAAP measure for third quarter 2026, compared with $0.1 million in the prior-year period
Cash and cash equivalents $3.7 million As of October 3, 2026; decreased $1.0 million from July 4, 2026
Adjusted operating expense guidance $19 million to $19.5 million Fiscal year 2026; excludes depreciation and amortization and stock-based compensation
Expected annualized savings Approximately $600,000 Expected from the completed headquarters relocation to San Jose
Adjusted EBITDA financial
"Non-GAAP adjusted EBITDA loss for the third quarter of 2026"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
pro forma gross margin financial
"pro forma gross margin was 38.7%"
stock-based compensation financial
"exclude depreciation and amortization and stock-based compensation"
Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.
third-party contract manufacturers technical
"transition of its major products to third-party contract manufacturers"
safety stock inventory technical
"consumption of the safety stock inventory"
Total revenue $10.2 million Down 19% from $12.5 million in the prior-year period
Gross margin 42.4% Compared with 32.1% in the prior-year period
Net loss $1.4 million Compared with $1.6 million in the prior-year period
Non-GAAP adjusted EBITDA loss $0.6 million Compared with $0.1 million in the prior-year period
Operating expenses $5.5 million Compared with $5.4 million in the prior-year period
Cash and cash equivalents $3.7 million Decreased $1.0 million from July 4, 2026
Guidance

Full-year 2026 revenue guidance was reduced to $46 million to $48 million from $51 million to $53 million and continues to exclude Middle East revenue. Adjusted operating expenses are expected to be $19 million to $19.5 million, excluding depreciation and amortization and stock-based compensation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What drove IRIDEX’s higher gross margin in the third quarter of 2026?

Gross margin was 42.4%, compared with 32.1% in the prior-year period. IRIDEX attributed the improvement to the prior-year quarter’s approximately $0.8 million write-off to cost of goods sold, more favorable geographic mix and sustained pricing discipline.

Why did IRIDEX revenue decline in the third quarter of 2026?

Revenue declined primarily because of lower international retina sales and lower international probe orders, partially offset by growth in the U.S. glaucoma business. The company also cited weaker-than-expected demand in Europe and Asia, distributor inventory drawdowns and late-quarter order delays.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000100604500010060452026-11-172026-11-17

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

November 17, 2026

 

(Date of Report (date of earliest event reported)

 

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

000-27598

77-0210467

(State or other jurisdiction of
incorporation or organization)

(Commission File Number)

(I.R.S. Employer
Identification Number)

5215 Hellyer Avenue, Suite 150
San Jose, California 95138

(Address of principal executive offices, including zip code)

 

(650) 940-4700

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of Class

 

Trading

Symbol

 

Name of Exchange on Which Registered

Common Stock, par value $0.01 per share

 

IRIX

 

Nasdaq Capital Market

 

 


 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 17, 2026, IRIDEX Corporation issued a press release discussing its financial results for its third fiscal quarter ended October 3, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

 

(d)

Exhibits

 

Exhibit No.

Description

99.1

Press Release dated November 17, 2026.

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

-2-


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

IRIDEX CORPORATION

 

 

 

 

 

By:

 

/s/ Romeo R. Dizon

 

 

 

Romeo R. Dizon

 

 

 

Chief Financial Officer

 

 

 

 

Date: November 17, 2026

 

 

 

 

-3-


 

Exhibit 99.1

img156381773_0.jpg

Iridex Reports Third Quarter 2026 Financial Results
 

SAN JOSE, Calif., November 17, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 3, 2026.

Third Quarter 2026 Financial Highlights

•
Generated total revenue of $10.2 million, compared to $12.5 million in the prior year period
•
Cyclo G6® product family revenue was $3.2 million, compared to $3.5 million in the prior year period
o
Sold approximately 11,900 Cyclo G6 probes compared to 14,900 in the prior year period
o
Sold 28 Cyclo G6 Glaucoma Laser Systems compared to 30 in the prior year period
•
Retina product revenue was $5.1 million compared to $6.7 million in the prior year period
•
Gross margin increased to 42.4%, compared to 32.1% in the prior year period and 34.2% in the second quarter of 2026
•
Completed headquarter relocation to San Jose, expected to deliver approximately $600,000 in annualized savings

“On the top line, revenue came in below our expectations this quarter, driven by weaker than anticipated customer demand in Europe and Asia coupled with order delays late in the quarter as distributors worked through probe inventory and ongoing regulatory challenges. At the same time, we continue to experience the benefits from the cost savings programs initiated when I was named CEO, including the recent relocation of our headquarters,” said Patrick Mercer, President and CEO of Iridex.

 

“Considering the lower revenue and our investment in inventory to manage the manufacturing facility transition, cash utilization during the quarter was only $1 million and should decrease significantly in the fourth quarter with stronger sales and reversal of the inventory stocking process,” Mercer continued. “We are now deep into a strategic review of our product lines, and as part of that work we are reprioritizing our resources toward our most profitable opportunities. With this focus, we expect to enter 2027 with better margins, a lower cost base, and a business model better aligned toward cash flow generation.”

 

Third Quarter 2026 Financial Results

Total revenue for the three months ended October 3, 2026 was $10.2 million, representing a decline of 19% compared to the third quarter of 2025. The decrease was primarily driven by lower international retina sales and lower international probe orders, partially offset by growth in the U.S. glaucoma business. Total retina product revenue was $5.1 million compared to $6.7 million in the prior year period. The decrease was driven by international markets and external headwinds. Total product


revenue from the Cyclo G6 product family was $3.2 million, compared to $3.5 million in the prior year period. International revenue declined as distributors elected to work through inventory purchased earlier in the year, partially offset by higher U.S. probe average selling prices and higher system revenue. Other revenue was $1.9 million compared to $2.2 million in the prior year period, mainly reflecting lower service revenue and the absence of royalty revenue in the current period.

Gross margin in the third quarter of 2026 was 42.4%, compared to 32.1%, in the prior year period. The improvement reflects a one-time write off recorded during the third quarter of 2025 of approximately $0.8 million to cost of goods sold and more favorable geographic mix and sustained pricing discipline. Excluding this impact, pro forma gross margin was 38.7%, representing a solid 370 basis point improvement. The Company expects the transition of its major products to third-party contract manufacturers to be the next significant driver of margin expansion through 2027.

Operating expenses were $5.5 million in the third quarter of 2026, essentially flat compared to $5.4 million in the third quarter of 2025.

 

Net loss was $1.4 million, or $0.08 per share, for the third quarter of 2026, compared to a net loss of $1.6 million, or $0.09 per share, in the same period of the prior year.

 

Non-GAAP adjusted EBITDA loss for the third quarter of 2026 was $0.6 million, compared to a non-GAAP adjusted EBITDA loss of $0.1 million for the third quarter of 2025.

Cash and cash equivalents as of October 3, 2026 were $3.7 million, a decrease of $1.0 million compared to July 4, 2026. Cash utilization is expected to decrease significantly with stronger sales and consumption of the safety stock inventory.

 

2026 Financial Outlook

Based on third quarter trends, which the Company expects to continue through the fourth quarter, the Company is reducing its annual revenue guidance for the full year 2026 to between $46 million and $48 million, from the prior range of $51 million to $53 million. This guidance continues to exclude revenue from the Middle East.

 

The Company continues to expect fiscal year 2026 adjusted operating expenses, which exclude depreciation and amortization and stock-based compensation, to be in the range of $19 million to $19.5 million.

Webcast and Conference Call Information

Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com or by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 7118799.

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the


treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.

 

For additional information, visit www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning commercial trends, market adoption and expansion, expectations regarding profitability, demand for and utilization of the Company's products, financial results and forecasts and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks further described in the “Risk Factors” section of Iridex’s most recent Annual Report on Form 10-K, as well as in Iridex’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

 

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Iridex’s GAAP results, we consider Adjusted EBITDA. This

non-GAAP result should not be considered as an alternative to net income, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present this non-GAAP result because management considers it to be an important supplemental measure of Iridex’s performance and refers to such measures when analyzing Iridex’s strategy and operations.

In calculating the above non-GAAP result: Adjusted EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Adjusted EBITDA exclude from their GAAP equivalents items listed below:

•
Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Iridex.
•
Severance-related expenses. We excluded from our non-GAAP results the expenses related to restructuring events, partially offset by reversals of previously recognized severance expenses in subsequent periods. These expenses are unrelated to our ongoing operations, vary in size and frequency and are subject to significant fluctuations from period to period due to varying levels of restructuring activity. We believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
•
Reconvention of shareholders’ meeting expenses. We excluded from our non-GAAP results the expenses related to the costs of reconvening our latest annual shareholders meeting. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.

•
Legal settlement expenses. We excluded from our non-GAAP results the expenses related to the non-recurring settlement of a legal case regarding the use of tracking software on the Company's website. We believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
•
Loss on write-down of inventory. We excluded from our non-GAAP results the expenses related to the write down of inventory related to the transfer of production of several products to 3rd party contract manufacturers. In these types of transactions, not all applicable inventories are acquired by the contract manufacturers and thus, such inventory becomes excess and obsolete. These expenses are unrelated to our ongoing operations, and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.

 

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.

A detailed reconciliation between Iridex’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Iridex’s other reports filed with or furnished to the SEC.

 

Investor Relations Contact

Philip Taylor

Gilmartin Group

investors@iridex.com


 

img156381773_1.jpg

IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

October 3, 2026

 

 

September 27, 2025

 

 

October 3, 2026

 

 

September 27, 2025

 

Total revenues

 

$

10,156

 

 

$

12,484

 

 

$

34,521

 

 

$

37,951

 

Cost of revenues

 

 

5,854

 

 

 

8,471

 

 

 

21,182

 

 

 

24,201

 

Gross profit

 

 

4,302

 

 

 

4,013

 

 

 

13,339

 

 

 

13,750

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

1,014

 

 

 

972

 

 

 

2,855

 

 

 

2,719

 

Sales and marketing

 

 

2,408

 

 

 

2,657

 

 

 

7,492

 

 

 

7,645

 

General and administrative

 

 

2,043

 

 

 

1,795

 

 

 

5,508

 

 

 

5,942

 

Total operating expenses

 

 

5,465

 

 

 

5,424

 

 

 

15,855

 

 

 

16,306

 

Loss from operations

 

 

(1,163

)

 

 

(1,411

)

 

 

(2,516

)

 

 

(2,556

)

Other expense, net

 

 

(160

)

 

 

(158

)

 

 

(469

)

 

 

(1,660

)

Loss from operations before provision for income taxes

 

 

(1,323

)

 

 

(1,569

)

 

 

(2,985

)

 

 

(4,216

)

Provision for income taxes

 

 

78

 

 

 

4

 

 

 

206

 

 

 

37

 

Net loss

 

$

(1,401

)

 

$

(1,573

)

 

$

(3,191

)

 

$

(4,253

)

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.08

)

 

$

(0.09

)

 

$

(0.18

)

 

$

(0.25

)

Diluted

 

$

(0.08

)

 

$

(0.09

)

 

$

(0.18

)

 

$

(0.25

)

Weighted average shares used in computing net loss per common share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

17,593

 

 

 

17,009

 

 

 

17,441

 

 

 

16,843

 

Diluted

 

 

17,593

 

 

 

17,009

 

 

 

17,441

 

 

 

16,843

 

 


img156381773_1.jpg

IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands)

 

 

October 3, 2026

 

 

January 3, 2026

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

3,673

 

 

$

6,028

 

Accounts receivable, net

 

 

4,775

 

 

 

9,545

 

Inventories

 

 

11,760

 

 

 

7,877

 

Prepaid expenses and other current assets

 

 

2,611

 

 

 

1,802

 

Total current assets

 

 

22,819

 

 

 

25,252

 

Property and equipment, net

 

 

210

 

 

 

58

 

Intangible assets, net

 

 

745

 

 

 

984

 

Goodwill

 

 

965

 

 

 

965

 

Operating lease right-of-use assets, net

 

 

3,615

 

 

 

768

 

Other long-term assets

 

 

918

 

 

 

1,124

 

Total assets

 

$

29,272

 

 

$

29,151

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

7,077

 

 

$

5,502

 

Accrued compensation

 

 

1,443

 

 

 

2,340

 

Accrued expenses

 

 

579

 

 

 

608

 

Other current liabilities

 

 

1,627

 

 

 

1,899

 

Deferred revenue, current

 

 

2,215

 

 

 

2,160

 

Operating lease liabilities, current

 

 

48

 

 

 

699

 

Total current liabilities

 

 

12,989

 

 

 

13,208

 

Long-term liabilities:

 

 

 

 

 

 

Deferred revenue

 

 

5,702

 

 

 

6,801

 

Operating lease liabilities

 

 

3,561

 

 

 

98

 

Convertible note payable

 

 

3,825

 

 

 

3,735

 

Other long-term liabilities

 

 

568

 

 

 

387

 

Total liabilities

 

 

26,645

 

 

 

24,229

 

Stockholders’ equity:

 

 

 

 

 

 

Series B convertible preferred stock

 

 

6,000

 

 

 

6,000

 

Common stock

 

 

178

 

 

 

174

 

Additional paid-in capital

 

 

92,100

 

 

 

91,208

 

Accumulated other comprehensive loss

 

 

(14

)

 

 

(14

)

Accumulated deficit

 

 

(95,637

)

 

 

(92,446

)

Total stockholders’ equity

 

 

2,627

 

 

 

4,922

 

Total liabilities and stockholders’ equity

 

$

29,272

 

 

$

29,151

 

 

 

 

 

 

 

 

 


img156381773_1.jpg

IRIDEX Corporation

Reconciliation of GAAP Net Loss to Adjusted EBITDA

(In thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

October 3, 2026

 

 

September 27, 2025

 

 

October 3, 2026

 

 

September 27, 2025

 

Reconciliation of GAAP net loss to Adjusted EBITDA(a)

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss

 

$

(1,401

)

 

$

(1,573

)

 

$

(3,191

)

 

$

(4,253

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

(4

)

 

 

(10

)

 

 

(16

)

 

 

(31

)

Other expense

 

 

164

 

 

 

167

 

 

 

485

 

 

 

1,691

 

Provision for income taxes

 

 

78

 

 

 

4

 

 

 

206

 

 

 

37

 

Nasdaq listing compliance

 

 

-

 

 

 

-

 

 

 

-

 

 

 

152

 

Reconvention of shareholders' meeting expenses

 

 

67

 

 

 

-

 

 

 

129

 

 

 

-

 

Legal settlement expenses

 

 

-

 

 

 

-

 

 

 

40

 

 

 

-

 

Depreciation and amortization

 

 

260

 

 

 

366

 

 

 

994

 

 

 

1,125

 

Inventory write-down

 

 

-

 

 

 

823

 

 

 

-

 

 

 

823

 

Stock-based compensation

 

 

182

 

 

 

92

 

 

 

605

 

 

 

562

 

Severance related expense (for head count reduction)

 

 

74

 

 

 

-

 

 

 

74

 

 

 

199

 

Adjusted EBITDA

 

$

(580

)

 

$

(131

)

 

$

(674

)

 

$

305

 

 

(a)Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as certain non-GAAP adjustments.


Filing Exhibits & Attachments

2 documents

Keep reading